References
- Manca A, Rice N, Sculpher MJ. Assessing generalizability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Economics 2005; 14: 471–485.
- Grieve R, Nixon R, Thompson S et al. Using multilevel models for assessing the variability of multinational resource use and cost data. Health Economics 2005; 14: 185–196.
- Willan AR, Pinto EM, O’Brien BJ et al. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. Health Economics 2005; 14: 327–338.
- Taylor RS, Drummond MF, Salkeld G, Sullivan SD. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. Brtish Medical Journal 2004; 329: 972–975.
- Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis and Rheumatism 1999; 42(6): 1209–1218.
- Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis and Rheumatism 1999; 42(2): 347–356.
- Sullivan AKO, Thompson D, Drummond MF. Collection of health- economic data alongside clinical trials: Is there a future for piggyback evaluations? Value in Health 2005; 8(1): 67–79.
- Drummond MF. Will there be a European drug pricing and reimbursement agency? European Health Economics 2003; 4: 67–69.
- Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of the conflict of interest in economic analyses of new drugs used in oncology. Journal of the American Medical Association 1999; 282:1453-1457
- Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systemic review. Brtish Medical Journal 2003; 326: 1167-1170.